The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy and Metabolic Effects

BACKGROUND: A current limitation of islet transplantation is reduced long term graft function. The glucagon like peptide-1 (GLP-1) receptor agonist, exenatide (Byetta(®), Amylin Pharmaceuticals, CA) has properties that could improve existing islet function, prevent further loss of islet mass and pos...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Froud, Tatiana, Faradji, Raquel N., Pileggi, Antonello, Messinger, Shari, Baidal, David A., Ponte, Gaston M., Cure, Pablo E., Monroy, Kathy, Mendez, Armando, Selvaggi, Gennaro, Ricordi, Camillo, Alejandro, Rodolfo
Formato: Artigo
Lenguaje:Inglês
Publicado: 2008
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2772201/
https://ncbi.nlm.nih.gov/pubmed/18622276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0b013e31817c4ab3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares